Spots Global Cancer Trial Database for protein kinase inhibitors
Every month we try and update this database with for protein kinase inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. | NCT00676299 | Protein Kinase ... Antineoplastic ... Clinical Trial,... Maximum Tolerat... Pharmacokinetic... Advanced Malign... Solid Malignanc... | JNJ-26483327 | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Savolitinib vs. Sunitinib in MET-driven PRCC. | NCT03091192 | Carcinoma Carcinoma, Rena... Kidney Neoplasm... Urologic Neopla... Kidney Diseases Neoplasms by Si... Enzyme Inhibito... Protein Kinase ... | Savolitinib Sunitinib | 18 Years - 130 Years | AstraZeneca | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | NCT01725204 | Leukemia, Myelo... | Dasatinib + Peg... | 18 Years - 70 Years | Norwegian University of Science and Technology | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | NCT01725204 | Leukemia, Myelo... | Dasatinib + Peg... | 18 Years - 70 Years | Norwegian University of Science and Technology | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | NCT01199068 | Carcinoma, Non-... | CS-7017 Erlotinib | 18 Years - | Daiichi Sankyo | |
| Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | NCT01024413 | Thoracic Neopla... | erlotinib gefitinib | - | Chinese Society of Lung Cancer | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors | NCT01764087 | Unspecified Adu... Gastric Cancer Breast Cancer | KX2-391 and Pac... | 20 Years - | Hanmi Pharmaceutical Company Limited | |
| Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | NCT00867113 | Gastrointestina... | imatinib mesyla... | 18 Years - | Novartis | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Study of Oral JYP0322 in Patients With Locally Advanced or Metastatic Cancer Targeting ROS1 Molecular Fusion. | NCT06128148 | Protein Kinase ... Other Protocol ... Lung Neoplasms Brain Neoplasms | JYP0322 | 18 Years - | Guangzhou JOYO Pharma Co., Ltd | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | NCT05153408 | Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ... | BLU-701 osimertinib carboplatin pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | NCT02820961 | Breast Cancer Estrogen Recept... | entinostat exemestane | 18 Years - 85 Years | Syndax Pharmaceuticals | |
| Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib | NCT02056080 | Breast Neoplasm | 18 Years - | MedSIR | ||
| A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer | NCT01039948 | Carcinoma, Non-... Lung Neoplasms Lung Cancer Respiratory Tra... | AV-299 + gefiti... Gefitinib | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| International Chronic Myeloid Leukemia Pediatric Study | NCT01281735 | Chronic Myeloid... | - 18 Years | Poitiers University Hospital | ||
| Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | NCT01024413 | Thoracic Neopla... | erlotinib gefitinib | - | Chinese Society of Lung Cancer | |
| Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | NCT01725204 | Leukemia, Myelo... | Dasatinib + Peg... | 18 Years - 70 Years | Norwegian University of Science and Technology | |
| (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | NCT05241873 | Lung Neoplasm M... Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... EGFR Exon 20 Mu... EGFR Exon 20 In... EGFR Activating... Antineoplastic ... Metastatic Lung... Brain Metastase... EGFR-mutated NS... EGFR Atypical M... | BLU-451 Carboplatin Pemetrexed | 18 Years - | Blueprint Medicines Corporation | |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | NCT04518852 | Hepatocellular ... Liver Neoplasms Digestive Syste... Sorafenib Molecular Mecha... Liver Diseases Antineoplastic ... Protein Kinase ... | TACE combined w... | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| International Chronic Myeloid Leukemia Pediatric Study | NCT01281735 | Chronic Myeloid... | - 18 Years | Poitiers University Hospital | ||
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | NCT04862780 | Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla... | BLU-945 osimertinib | 18 Years - | Blueprint Medicines Corporation | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | NCT06190899 | mCRPC (Metastat... Genital Disease... Urogenital Dise... Prostatic Disea... Prostatic Neopl... Prostate Cancer | Gedatolisib Darolutamide | 18 Years - | Celcuity Inc | |
| An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® | NCT02455024 | Myeloid Leukemi... | 18 Years - | Takeda | ||
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | NCT01594398 | Lung Cancer Non Small Cell ... Breast Cancer Estrogen Recept... | entinostat entinostat Erlotinib Erlotinib Exemestane Exemestane | 18 Years - 90 Years | Syndax Pharmaceuticals | |
| Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) | NCT00867113 | Gastrointestina... | imatinib mesyla... | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
